生物科技公司Harmony Biosciences Holdings, Inc.（纳斯达克股票代码：HRMY）今日盘中大涨5.01%，投资者对公司最新发布的强劲财报及业务增长表现出积极反应。
根据公司最新公布的2025年第三季度财报，Harmony Biosciences的平均患者数量创下新高，较上一季度增加约500人，达到8,100人。这一显著增长表明公司的市场渗透率持续提升，产品需求强劲。与此同时，公司还上调了2025年全年收入指引，从此前的预期提高至8.45亿-8.65亿美元，反映出管理层对未来业绩增长的信心。
分析人士指出，Harmony Biosciences的业务表现优于预期，尤其是在患者数量增长和收入指引上调方面的亮眼表现，极大地提振了投资者信心。这些积极因素共同推动了公司股价的显著上涨，反映出市场对Harmony Biosciences未来发展前景的看好。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.